Head-To-Head Analysis: Organogenesis (NASDAQ:ORGO) vs. Agile Therapeutics (NASDAQ:AGRX)

Organogenesis (NASDAQ:ORGO) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Risk and Volatility

Organogenesis has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares Organogenesis and Agile Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organogenesis	1.14%	1.81%	1.09%
Agile Therapeutics	-73.83%	N/A	-179.07%

Earnings & Valuation

This table compares Organogenesis and Agile Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$433.14 million	0.87	$4.95 million	$0.04	71.52
Agile Therapeutics	$19.59 million	0.14	-$14.47 million	($9.84)	-0.04

Organogenesis has higher revenue and earnings than Agile Therapeutics. Agile Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are held by institutional investors. 34.0% of Organogenesis shares are held by company insiders. Comparatively, 0.5% of Agile Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Organogenesis and Agile Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0	1	2	0	2.67
Agile Therapeutics	0	1	1	0	2.50

Organogenesis presently has a consensus price target of $4.83, suggesting a potential upside of 69.00%. Agile Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 2,104.53%. Given Agile Therapeutics’ higher possible upside, analysts clearly believe Agile Therapeutics is more favorable than Organogenesis.

Summary

Organogenesis beats Agile Therapeutics on 13 of the 14 factors compared between the two stocks.

About Organogenesis

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

About Agile Therapeutics

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.